{"name":"Phoenicis Therapeutics","slug":"phoenicis-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPMHpITkR5enRaOGh0YlREQmxkUDdKOER2LUZUNnFjbGdEbC0zMUp5ODE4QjU0SVF5M3pac0dmUjE2UGg1a3ZKM281VDQyaTRmRTQ1X3dNanFOa2JNLW1iWGJ1c21uNDRyZG8xQ1daTmMtd0lwekZCTkQzZVpkUHE4dG1RLU55MDZMNmNPV0lrLW43ZEZ1OG12ekV1VnYyVEpKcE5LYmhLdnVQbV9JOXd3cnlCVS13OXJGeWp3OGo3MA?oc=5","date":"2026-03-17","type":"pipeline","source":"Nasdaq","summary":"Epidermolysis Bullosa Market Set for Significant Upswing During the Forecast Period (2025-2034) Amid Rising Therapeutic Advancements | DelveInsight - Nasdaq","headline":"Epidermolysis Bullosa Market Set for Significant Upswing During the Forecast Period (2025-2034) Amid Rising Therapeutic ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxPTGFlNmx0T2ZSSXpIclNPMjdnLVUxX3JkUHB1REtfbzdhcktLbkI5X3pVT0NWYXFKSGNFT1g5alRCNTlXOUs4R040V28tTXZrNXNrVzROYlFTTUtsMDQweldLYnY3cEZ2eU16ZjdkWnJmcENhaURsVTZ0MlJoYWpWd3lMdlMtR0thY3BpZEVaV3JWdFpWSm81ZjhUdnZSaEhyTDFDdjdzNF9pMC1IcmlZQjcwcWJxRTlsY2M0NHE1TUlxVDNPMDZ3RklpcjRCMHNRVnF5VzQzR3BUVWNyZF9JWUhyc210TzR6YzZjakp6cE9vRzIxOVRNWlVR?oc=5","date":"2025-05-22","type":"regulatory","source":"PR Newswire","summary":"ZEVASKYN Approval Positions Abeona as Emerging Player in Dystrophic Epidermolysis Bullosa Market | DelveInsight - PR Newswire","headline":"ZEVASKYN Approval Positions Abeona as Emerging Player in Dystrophic Epidermolysis Bullosa Market | DelveInsight","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOUGQydktVdXp6cXl5cUFma3I4eUdxZzNJblNqcDJLeWtrbjZ2dWpnN2NUd1ktcEhlWENHUGE3NkdIZlZEdWxORU1wb1NCa1k5bnJlTlpQaGhwMFR0eUtKSmU5Qkw5ZXhJZ29tUU0yVmwxcVotRkZMLUtaOVZkRzRBT1hycXIyWk9kU1p1TVByUlBpVjA0Smw0MEt3TERKRWNsVDdselJYcHBfY1JK?oc=5","date":"2022-11-21","type":"pipeline","source":"Fierce Biotech","summary":"Replay at it again, this time targeting rare skin disease with 2nd company launch - Fierce Biotech","headline":"Replay at it again, this time targeting rare skin disease with 2nd company launch","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}